According to the official website of the National Health Insurance Administration, on January 29, 2023, the State Food and Drug Administration conditionally approved the listing of the COVID-19 infection treatment drug rimivvir deuterium hydrobromide tablets (trade name: Mindevi) declared by Shanghai Wangshi Biomedical Technology Co., Ltd., and the COVID-19 infection treatment drug combination packaging of cinoltavir tablets/ritonavir tablets (trade name: cinoxin) declared by Hainan Xiansheng Pharmaceutical Co., Ltd. The head of the Medical Management Department of the State Health Insurance Bureau answered the reporter's questions about the current payment policy of the medical insurance for these two drugs. The person in charge introduced that according to the provisions of the Diagnosis and Treatment Plan for novel coronavirus Infection (Tenth Edition for Trial Implementation) of the National Health Commission, the above two drugs are all within the scope of the Tenth Edition. On January 30, the National Health Insurance Bureau printed and distributed documents, requiring all provincial medical security departments to, according to the requirements of the Notice of the National Health Insurance Bureau, the Ministry of Finance, the National Health Commission and the National Disease Control Bureau on Optimizing the Medical Security Policies for Patients with novel coronavirus Infection after the Implementation of the "Class B Management" (Yi Bao Fa [2023] No. 1) The two drugs in the combination package of Zenotevir tablets/Ritonavir tablets are temporarily included in the payment scope of the basic medical insurance fund of the province, and will be paid until March 31, 2023; At the same time, the relevant provincial medical insurance bureaus are required to perform the duties of the drug price authorities according to law, accept and guide the first offer of related drugs in accordance with the Guidelines for the Formation of the Price of COVID-19 Therapeutic Drugs (Trial), disclose the price composition information, and accept social supervision. At present, all domestic COVID-19 therapeutic drugs approved for listing have been included in the medical insurance payment scope. Among them, the traditional Chinese medicine "three drugs and three parties" and Azudine tablets have been officially included in the list of medical insurance drugs, and the combined packaging of Deuteromidevir Hydrobromide Tablets, Synotravir Tablets/Ritonavir Tablets and other drugs have been temporarily included in the scope of medical insurance payment. With regard to reducing the treatment cost of COVID-19 and improving the medical insurance guarantee ability, the National Health Insurance Bureau, the Ministry of Finance, the National Health Commission and the National Bureau for Disease Control and Prevention jointly released the Policy on Optimizing the Medical Security for Patients with novel coronavirus Infection after the Implementation of "Class B and Class B", and made it clear in the policy interpretation that we should continue to do a good job in price negotiations or consultations, centralized procurement, online procurement Filing procurement, price monitoring and other work to reduce the treatment cost of patients with COVID-19. The provincial medical insurance department should combine the actual operation of local medical insurance funds, promote the implementation of policies as a whole, and scientifically determine the scope and level of insurance, so as to not only reasonably reduce the burden of the masses, but also ensure the safety and sustainability of medical insurance funds. On this basis, if the medical insurance fund does not meet the needs of the overall planning area, it can be appropriately subsidized by the local finance. Timely promote the adjustment of funds in the province. (Xinhua News Agency)